# JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

> **NCT06751485** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 430 (estimated)

## Conditions studied

- Ovarian Cancer
- Primary Peritoneal
- Fallopian Tube Cancers

## Interventions

- **DRUG:** JSKN003
- **DRUG:** Doxorubicin
- **DRUG:** Paclitaxel
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT06751485
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-15
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751485, "JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06751485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*